8-K: Aquestive Raises $85M in Stock Offering for Anaphylm Launch

Aquestive Therapeutics, Inc. priced an underwritten public offering of 21.25 million shares of common stock at $4.00 per share, expecting to raise $85 million in gross proceeds to fund Anaphylm commercialization and general corporate purposes.

Summary

• Aquestive Therapeutics, Inc. entered into an underwriting agreement on August 14, 2025, for an underwritten offering of 21,250,000 shares of its common stock.
• The shares were priced at $4.00 per share, resulting in expected gross proceeds of $85.0 million before deducting underwriting discounts and estimated offering expenses.
• The offering is expected to close on August 15, 2025, subject to customary closing conditions.
• The net proceeds, combined with existing cash, are intended to primarily advance the launch and commercialization of Anaphylm (epinephrine) Sublingual Film, assuming FDA approval, and for working capital, capital expenditures, and general corporate purposes.
• The company believes these funds will enable it to fund planned operating expenses and capital expenditures into 2027.
• The offering was led by RTW Investments, LP, with participation from Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, Sio Capital Management, ADAR1 Capital Management, and Nantahala Capital.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful capital raise, which provides crucial funding for the commercialization of a key product candidate (Anaphylm) and extends the company's financial runway. However, the significant share dilution tempers the overall positive impact.

Positives

• Secured $85.0 million in gross proceeds, providing significant capital for strategic initiatives.
• Funds are primarily allocated to advance the launch and commercialization of Anaphylm, a key product candidate.
• The offering is expected to extend the company's financial runway into 2027, enhancing liquidity and operational stability.
• Strong institutional investor participation, including RTW Investments, LP, indicates confidence in the company's prospects.

Negatives

• The issuance of 21,250,000 new shares of common stock will result in dilution for existing shareholders.

Risks

• Actual results may differ materially from forward-looking statements due to risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering.
• The use of proceeds for Anaphylm commercialization is contingent upon United States Food and Drug Administration (FDA) approval.
• Additional factors that could cause actual results to differ materially are disclosed in the company's filings with the SEC, including the 'Risk Factors' section in its annual report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company intends to use the net proceeds from the offering, along with existing cash, primarily to advance the launch and commercialization of Anaphylm (epinephrine) Sublingual Film, assuming FDA approval. These funds are expected to enable the company to cover planned operating expenses and capital expenditures into 2027.

Management Comments

• The company intends to use the net proceeds received from the offering, together with its existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration approval, and for working capital, capital expenditures and general corporate purposes.

Industry Context

This equity offering is a common strategy for pharmaceutical and biotech companies, particularly those with late-stage product candidates like Anaphylm, to secure capital for commercialization efforts. The participation of specialized life sciences investors underscores the sector's interest in novel drug delivery platforms and potential market disruptors in areas like anaphylaxis treatment.

Comparison to Industry Standards

• The structure of this underwritten public offering, including the use of a shelf registration statement and customary closing conditions, aligns with standard capital raising practices for publicly traded biotech companies.
• The 90-day lock-up agreements for directors, officers, and affiliated securityholders are a typical measure to demonstrate commitment and stability post-offering, consistent with industry norms.
• The involvement of multiple investment banks (Leerink Partners, Cantor, Oppenheimer, H.C. Wainwright & Co., Brookline Capital Markets) as underwriters is standard for offerings of this size and type in the biotech sector.
• The stated use of proceeds for commercialization of a late-stage product candidate (Anaphylm) and extending financial runway is a common and expected allocation of funds for a company in this development phase, comparable to peers like Aardvark BioPharma's recent Series C funding for their lead oncology asset or Zebra Therapeutics' equity raise for their gene therapy launch.

Corporate Governance

Related Party Transactions

• RTW Investments, LP led the underwritten offering, indicating a significant investment in the company's common stock.
• An affiliate of RTW has agreed to a potential $75 million revenue interest purchase and sale agreement (RIPSA) with Aquestive, contingent upon FDA approval of Anaphylm and refinancing of existing notes. This agreement involves future royalty payments on Anaphylm net sales and a maximum buy-out amount of up to $225 million.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new common stock, potentially impacting per-share earnings and ownership percentage.
• The capital raise provides financial stability and resources, which could benefit shareholders by enabling the successful commercialization of Anaphylm and extending the company's operational runway.
• Employees may benefit from increased job security and resources for product development and commercialization, supporting the company's growth trajectory.

Next Steps

• The offering is expected to close on August 15, 2025, subject to customary closing conditions.
• Advance the launch and commercialization of Anaphylm (epinephrine) Sublingual Film, contingent on FDA approval.
• Continue to fund planned operating expenses and capital expenditures into 2027 with the raised capital.

Key Dates

Recommendation

The successful pricing of this $85 million equity offering provides crucial capital for Aquestive Therapeutics to advance the commercialization of Anaphylm, a key product candidate. This significantly extends the company's financial runway into 2027, reducing immediate liquidity concerns. However, the issuance of 21.25 million new shares at $4.00 per share represents substantial dilution for existing shareholders. While the funding is positive for long-term strategic execution, particularly for a biotech company nearing a major product launch, the immediate dilution and the inherent risks associated with FDA approval and commercial success of Anaphylm warrant a cautious 'Hold' recommendation. Investors should monitor Anaphylm's regulatory progress and market acceptance.

Keywords

Aquestive Therapeutics, AQST, equity offering, capital raise, underwritten offering, Anaphylm, epinephrine, pharmaceutical, biotech, commercialization, FDA approval, common stock